

Third-quarter 2020 results



Worldwide sales
\$12.6 billion

GAAP EPS
\$1.16

Non-GAAP EPS
\$1.74

2020 Financial outlook

- Company narrows and raises 2020 full-year revenue range to be between \$47.6 billion and \$48.6 billion, including a negative impact from foreign exchange of approximately 1.5%
- Company narrows and lowers 2020 full-year GAAP EPS range to be between \$4.55 and \$4.65; narrows and raises 2020 full-year Non-GAAP EPS range to be between \$5.91 and \$6.01, including a negative impact from foreign exchange of approximately 2.5%



“We continue to execute on our strategic priorities and remain confident we will achieve solid full-year revenue growth despite the impact of the ongoing COVID-19 pandemic. Demand for our products remains robust, and production, supply and distribution of our medicines, vaccines and animal health products are moving forward with minimal disruption.”

“I am confident in our ability to advance our promising pipeline and clinical trials despite the challenging environment, and I believe that our leadership and track record of solid commercial execution will continue to drive long-term growth.”

Ken Frazier
Chairman & CEO

COVID-19 Research highlights

Driving multiple scientific programs in an effort to help combat COVID-19

Antiviral candidate	Vaccine candidates	
Molnupiravir (MK-4482)	V591 (measles virus vector)	V590 (rVSV)
<p>Collaboration with Ridgeback Bio to develop molnupiravir (MK-4482), an orally available antiviral candidate in development for the treatment of patients with COVID-19.</p> <p>In preclinical studies, molnupiravir has shown antiviral activity against SARS-CoV-2, as well as the coronaviruses responsible for MERS and SARS. Results from a Phase 1 study suggest compound is well tolerated.</p> <p>MSD has initiated two large pivotal Phase 2/3 trials studying molnupiravir:</p> <ul style="list-style-type: none"> • One anticipated to enroll ~1,450 non-hospitalized adult COVID-19 patients • Another planned to enroll ~1,300 hospitalized adult COVID-19 patients <p>We have secured manufacturing capacity to produce millions of doses of molnupiravir before the end of the year.</p>	<p>V591, a SARS-CoV-2 vaccine candidate that uses a measles virus vector platform, has entered Phase 1 development.</p> <p>Clinical trials are being conducted in Europe and the U.S. These studies will inform dose formulation and dosing regimen decisions for a large Phase 3 clinical trial.</p> <p>Acquisition of Themis to develop an investigational vaccine against SARS-CoV-2 using Themis' innovative measles virus vector platform.</p>	<p>V590, a SARS-CoV-2 vaccine candidate that uses a recombinant vesicular stomatitis virus (rVSV) platform, will be entering Phase 1 development shortly.</p> <p>rVSV is the basis for MSD's Ebola Zaire virus vaccine, ERVEBO, which is the first rVSV vaccine approved for use in humans.</p> <p>Collaborating with IAVI to develop investigational vaccine against SARS-CoV-2 using rVSV technology.</p>

Creating long-term value for patients, employees and shareholders